Gilead Sciences (GILD) – General News
-
Midday movers: Diamondback Energy rises, Arm goes parabolic
-
Gilead to buy CymaBay for $4.3 billion in bets on liver disease treatment
-
Midday movers: Small cap stocks rule, Archer-Daniels-Midland falls, and more
-
Warner Bros, Bumble, Robinhood fall premarket; Rivian, Upwork, Take-Two rise
-
Gilead reports better-than-expected Q3 results amid stronger cancer drug sales
-
FDA forces Gilead Sciences' (GILD) to pause enrollment in US leukemia drug trials
-
Gilead profit beats Street expectations on COVID and HIV sales
-
Gilead, Kite in process of pausing Twitter advertising
-
Feds Seized Dozens of Shipments of Unauthorized Versions of Gilead Sciences' (GILD) Remdesivir - DJ
-
Wall Street closes lower as surging COVID-19 cases offset vaccine hopes
-
Don't use Gilead's remdesivir in hospitalised COVID-19 patients, WHO says
-
Wall Street closes higher, trade choppy as U.S. stimulus talks eyed
-
Remdesivir questioned by WHO trial; women take virus more seriously than men
-
U.S. pauses Eli Lilly trial of antibody drug Trump touted as COVID-19 'cure' over safety concern
-
Trump's Doctor Says He Continued to Improve, Not Entirely Out of Woods, Met Discharge Criteria
-
HHS says Gilead, distributor can directly sell COVID-19 drug in U.S.
-
Tech, healthcare mega deals boost virus-stricken M&A market
-
Gilead's shares rise after $21 billion deal for Immunomedics
-
Exclusive: U.S. hospitals turn down remdesivir, limit use to sickest COVID-19 patients
-
Gilead: FDA could expand remdesivir use despite mixed data
-
Gilead shares slide after FDA knocks back rheumatoid arthritis drug
-
Gilead seeks U.S. approval for COVID-19 treatment remdesivir
-
Pfizer to make Gilead's COVID-19 treatment remdesivir
-
EU buys remdesivir to treat 30,000 COVID patients, seeks more
-
Trump says virus will probably get worse before it gets better
-
Gilead analysis shows remdesivir reduced coronavirus death risk, more studies needed
-
Wall Street jumps with financials; Gilead data offsets virus fears
-
Gilead to deliver more remdesivir to Europe from autumn: WiWo
-
GSK to develop plant-based COVID-19 vaccine with Canada's Medicago
-
Wall Street ends higher on Boeing bump, stimulus eyed
-
Gilead targets remdesivir supply for two million COVID-19 patients by year-end
-
U.S. hospitals in hard hit regions step up use of steroids on sickest COVID-19 patients
-
Gilead's remdesivir shows modest improvement in moderate COVID-19 patients
-
Wall Street closes higher as recovery signs soothe protest, pandemic worries
-
Gilead study shows shorter five-day course of remdesivir works as well as 10-day one
-
Merck to buy Austrian vaccine maker as it jumps into COVID-19 race
-
U.S. doctors call for remdesivir data to guide coronavirus treatment
-
Will Gilead price its coronavirus drug for public good or company profit?
-
U.S. emergency approval broadens use of Gilead's COVID-19 drug remdesivir
-
Data on Gilead drug raises hopes in pandemic fight, Fauci calls it 'highly significant'
-
Wall Street rallies on promising coronavirus drug
-
S&P 500 slips after report on coronavirus drug trial
-
Wall Street gains on Boeing surge and coronavirus drug hopes
-
Futures jump late following data on potential virus treatment, Trump guidelines
-
Investors await data on coronavirus drugs as market rally builds
-
Trump says he slashed red tape for vaccines, therapies
-
Gilead buys Forty Seven for $4.9 billion to bolster cancer drug pipeline
-
Wall Street set for steep fall on alarm over fast-spreading virus
-
Availability of Vaccines Could be Year to Year and Half - HHS
-
Only one drug with real efficacy, remdesivir (GILD) - WHO Team in Beijing
Back to GILD Stock Lookup
